HER3 in cancer: from the bench to the bedside
Abstract The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is expressed in several types of tumors. That fact, together with the role of HER3 in promoting cell proliferation, implicate that targeting HER3 may have therapeutic relevance. Furthermore, expression and...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-10-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-022-02515-x |
| _version_ | 1828140583101661184 |
|---|---|
| author | Lucía Gandullo-Sánchez Alberto Ocaña Atanasio Pandiella |
| author_facet | Lucía Gandullo-Sánchez Alberto Ocaña Atanasio Pandiella |
| author_sort | Lucía Gandullo-Sánchez |
| collection | DOAJ |
| description | Abstract The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is expressed in several types of tumors. That fact, together with the role of HER3 in promoting cell proliferation, implicate that targeting HER3 may have therapeutic relevance. Furthermore, expression and activation of HER3 has been linked to resistance to drugs that target other HER receptors such as agents that act on EGFR or HER2. In addition, HER3 has been associated to resistance to some chemotherapeutic drugs. Because of those circumstances, efforts to develop and test agents targeting HER3 have been carried out. Two types of agents targeting HER3 have been developed. The most abundant are antibodies or engineered antibody derivatives that specifically recognize the extracellular region of HER3. In addition, the use of aptamers specifically interacting with HER3, vaccines or HER3-targeting siRNAs have also been developed. Here we discuss the state of the art of the preclinical and clinical development of drugs aimed at targeting HER3 with therapeutic purposes. |
| first_indexed | 2024-04-11T19:12:02Z |
| format | Article |
| id | doaj.art-ab1e967dfa2146b59981aefb16f60db2 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-04-11T19:12:02Z |
| publishDate | 2022-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-ab1e967dfa2146b59981aefb16f60db22022-12-22T04:07:36ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662022-10-0141112610.1186/s13046-022-02515-xHER3 in cancer: from the bench to the bedsideLucía Gandullo-Sánchez0Alberto Ocaña1Atanasio Pandiella2Instituto de Biología Molecular y Celular del Cáncer, CSIC, IBSAL and CIBERONCHospital Clínico San Carlos and CIBERONCInstituto de Biología Molecular y Celular del Cáncer, CSIC, IBSAL and CIBERONCAbstract The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is expressed in several types of tumors. That fact, together with the role of HER3 in promoting cell proliferation, implicate that targeting HER3 may have therapeutic relevance. Furthermore, expression and activation of HER3 has been linked to resistance to drugs that target other HER receptors such as agents that act on EGFR or HER2. In addition, HER3 has been associated to resistance to some chemotherapeutic drugs. Because of those circumstances, efforts to develop and test agents targeting HER3 have been carried out. Two types of agents targeting HER3 have been developed. The most abundant are antibodies or engineered antibody derivatives that specifically recognize the extracellular region of HER3. In addition, the use of aptamers specifically interacting with HER3, vaccines or HER3-targeting siRNAs have also been developed. Here we discuss the state of the art of the preclinical and clinical development of drugs aimed at targeting HER3 with therapeutic purposes.https://doi.org/10.1186/s13046-022-02515-xHER3Cancer therapyReceptor tyrosine kinases |
| spellingShingle | Lucía Gandullo-Sánchez Alberto Ocaña Atanasio Pandiella HER3 in cancer: from the bench to the bedside Journal of Experimental & Clinical Cancer Research HER3 Cancer therapy Receptor tyrosine kinases |
| title | HER3 in cancer: from the bench to the bedside |
| title_full | HER3 in cancer: from the bench to the bedside |
| title_fullStr | HER3 in cancer: from the bench to the bedside |
| title_full_unstemmed | HER3 in cancer: from the bench to the bedside |
| title_short | HER3 in cancer: from the bench to the bedside |
| title_sort | her3 in cancer from the bench to the bedside |
| topic | HER3 Cancer therapy Receptor tyrosine kinases |
| url | https://doi.org/10.1186/s13046-022-02515-x |
| work_keys_str_mv | AT luciagandullosanchez her3incancerfromthebenchtothebedside AT albertoocana her3incancerfromthebenchtothebedside AT atanasiopandiella her3incancerfromthebenchtothebedside |